All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The QUAZAR AML-001 trial has been extensively covered on our hub, with key results demonstrating that maintenance with oral azacitidine (AZA) improves overall survival (OS) and relapse-free survival (RFS) when compared with placebo in elderly patients with acute myeloid leukemia (AML) in first complete remission. At the European Hematology Association (EHA) 2022 Congress, Andrew Wei presented updated results for long-term survival with oral azacitidine from this trial,1 which we are pleased to summarize here.
In summary, updated results from the QUAZAR AML-001 trial demonstrated that treatment with oral azacitidine led to improved LTS outcomes compared with placebo (34.9% vs 24.4%). Oral azacitidine was also significantly associated with improved LTS in a multivariable analysis.
AML Hub (AML Global Portal): A note from the editor-in-chief
The AML Hub's editor-in-chief, Alexander Maurer, reports from the 61st American Society of Hematology (ASH) meeting in Orlando, US, and discusses some of the exciting advances in acute...
EBMT 2019 | Umbilical cord blood transplantation in adolescents and young adults with acute myeloid leukemia
This study aimed to investigate the use of UCBT in patients aged 15–25 with acute leukemia following a myeloablative conditioning regimen.
Subscribe to get the best content related to AML delivered to your inbox